What amount sold does INANOVATE INC report in Form D filings?

The latest linked filings report $13M sold across 10 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was INANOVATE INC's most recent SEC filing?

INANOVATE INC's most recent Form D filing was on 2025-07-02.

How many investors does INANOVATE INC have?

The most recent Form D filing lists 2 investor(s).

What type of securities does INANOVATE INC offer?

INANOVATE INC's SEC Form D filings indicate equity offerings.

INANOVATE INC

CIK: 0001366325·Biotechnology·SIOUX FALLS, SD·Corporation

Reported Sold

$12,952,638

Total Filings

Identified Offerings

Last Filed

Jul 2, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jul 2, 2025Form D — New notice

Reported sold: $808,000 · Target: $808,000

Rule 506(b)·2 investors

Nov 15, 2024Form D — New notice

Reported sold: $900,000 · Target: $900,000

Rule 506(b)·6 investors

Jun 12, 2024Form D — New notice

Reported sold: $1,100,000 · Target: $2,500,000

Rule 506(b)·4 investors

Dec 11, 2023Form D — New notice

Reported sold: $1,500,000 · Target: $3,000,000

Rule 506(b)·3 investors

Oct 6, 2022Form D — New notice

Reported sold: $2,390,000 · Target: $3,000,000

Rule 506(b)·7 investors

Feb 23, 2022Form D — New notice

Reported sold: $1,807,117 · Target: $1,807,117

Rule 506(b)·11 investors

Jul 13, 2020Form D — New notice

Reported sold: $455,260 · Target: $455,260

Rule 506(b)·6 investors

Nov 18, 2019Form D — New notice

Reported sold: $439,244 · Target: $439,244

Rule 506(b)·3 investors

Feb 19, 2019Form D — New notice

Reported sold: $3,050,609 · Target: $3,050,609

Rule 506(b)·5 investors

Dec 17, 2015Form D — New notice

Reported sold: $502,408 · Target: $2,000,000

Rule 506(b)·5 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

$1 - $1,000,000

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 10 identified offerings

$12,952,638

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Peter D Los

Related Person

Appears on 9 filings

James E Oury

Related Person

Appears on 9 filings

David Ure

Related Person

Appears on 9 filings

George Holmes

Related Person

Appears on 9 filings

David Arslanian

Related Person

Appears on 9 filings

Blaine Crissman

Related Person

Appears on 8 filings

Katie Pohlson

Related Person

Appears on 4 filings

Michael Goldstein

Related Person

Appears on 4 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 2, 2025	New	$808,000	$808,000	2
Nov 15, 2024	New	$900,000	$900,000	6
Jun 12, 2024	New	$2,500,000	$1,100,000	4
Dec 11, 2023	New	$3,000,000	$1,500,000	3
Oct 6, 2022	New	$3,000,000	$2,390,000	7
Feb 23, 2022	New	$1,807,117	$1,807,117	11
Jul 13, 2020	New	$455,260	$455,260	6
Nov 18, 2019	New	$439,244	$439,244	3
Feb 19, 2019	New	$3,050,609	$3,050,609	5
Dec 17, 2015	New	$2,000,000	$502,408	5

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Immuno Cancer Biotherapeutics, Inc.

Biotechnology

Offering target: Indefinite

Filed Oct 15, 2026